Cyclo Therapeutics/CYTH

$1.39

-2.8%
-
1D1W1MYTD1YMAX

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).

Ticker

CYTH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

N. Scott Fine

Employees

8

Headquarters

Gainesville, United States
Website
www.cyclotherapeutics.com

CYTH Metrics

BasicAdvanced
$40M
Market cap
-
P/E ratio
-$1.33
EPS
-0.29
Beta
-
Dividend rate
$40M
-0.28629
$2.57
$0.89
94K
1.455
1.425
-2,769.34%
-229.72%
-730.48%
-727.5%
37.615
8.464
8.511
-21.76%
27.06%
6.02%

What the Analysts think about CYTH

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
130.22% upside
High $4.00
Low $2.60
$1.39
Current price
$3.20
Average price target

CYTH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,866.66% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$300K
-25%
Net income
-$5.6M
19.15%
Profit margin
-1,866.66%
58.86%

CYTH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25%
QuarterlyAnnual
Q1 23
Q2 23
Q1 24
Actual
-$0.46
-$0.33
-
Expected
-$0.42
-$0.44
-$0.21
Surprise
9.52%
-25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cyclo Therapeutics stock?

Cyclo Therapeutics (CYTH) has a market cap of $40M as of May 16, 2024.

What is the P/E ratio for Cyclo Therapeutics stock?

The price to earnings (P/E) ratio for Cyclo Therapeutics (CYTH) stock is 0 as of May 16, 2024.

Does Cyclo Therapeutics stock pay dividends?

No, Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders as of May 16, 2024.

When is the next Cyclo Therapeutics dividend payment date?

Cyclo Therapeutics (CYTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Cyclo Therapeutics?

Cyclo Therapeutics (CYTH) has a beta rating of -0.29. This means that it has an inverse relation to market volatility.

What is the Cyclo Therapeutics stock price target?

The target price for Cyclo Therapeutics (CYTH) stock is $3.2, which is 130.22% above the current price of $1.39. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cyclo Therapeutics stock

Buy or sell Cyclo Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing